Ligand Pharmaceuticals has entered a worldwide licence agreement for US-based biotechnology company Surface Oncology to use its OmniAb platform.

Under the licence agreement, Surface Oncology will be able to use Ligand Pharmaceuticals’ OmniRat, OmniMouse and OmniFlic platforms in order to discover fully human, monospecific and bispecific antibodies.

US biopharmaceutical company Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments, as well as tiered royalties for each product incorporating an OmniAb antibody.

Surface Oncology will be responsible for all costs associated with the programmes.

Ligand Pharmaceuticals chief executive officer John Higgins said: “This agreement allows Surface Oncology to join a growing roster of companies with access to OmniAb, our novel transgenic rodent technology that goes beyond a transgenic mouse technology, adding a transgenic rat and a separate transgenic rat with fixed light chain antibodies to enable bispecific antibody discovery.

"This is the second OmniAb partnership announced within a week, further demonstrating the significant partnership interest that exists for this important, novel technology."

“This is the second OmniAb partnership announced within a week, further demonstrating the significant partnership interest that exists for this important, novel technology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OmniRat is the industry’s first human monoclonal antibody technology based on rats and has a complete immune system with a wide range of antibody repertoire, as well as generates antibodies with human idiotypes as effectively as wild-type animals make rat antibodies.

OmniMouse is a transgenic mouse that complements OmniRat and expands epitope coverage, while OmniFlic is an engineered rat with a fixed light chain for the development of bispecific, fully human antibodies.

Surface Oncology is an immuno-oncology company that develops advanced immunotherapies targeting the tumour microenvironment.